An algorithmic approach to close care gaps for patients that may benefit from confirmatory IHC HER2 testing

In partnership with a global pharmaceutical company, Tempus Next deployed a HER2 predictive algorithm at selected sites within the Tempus network. This algorithm was used during routine xR (whole transcriptome RNA) tests to identify patients who may benefit from additional confirmatory IHC HER2 testing.